• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Teva Pharmaceutical Industries Limited

    3/5/26 5:49:15 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TEVA alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0002025621
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    TEVA PHARMACEUTICAL INDUSTRIES LTD
    SEC File Number
    001-16174
    Address of Issuer
    TEVA PHARMACEUTICAL INDUSTRIES LIMITED
    124 DVORA HANEVI'A ST.
    TEL AVIV
    ISRAEL
    6944020
    Phone
    972 (3) 914-8213
    Name of Person for Whose Account the Securities are To Be Sold
    Shields Matthew
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer
    Relationship to Issuer
    EXECUTIVE VP TEVA GLOBAL OPERATIONS

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    ORDINARY SHARES
    CITIGROUP GLOBAL MARKETS
    390 GREENWICH ST
    NEW YORK � NY � 10013
    17295547704.98114981289803/05/2026
    NYSE


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    ORDINARY SHARES03/05/2025RESTRICTED SHARE UNIT AWARD VESTINGTEVA PHARMACEUTICAL INDUSTRIES LIMITEDCheckbox not checked1729503/05/2026COMPENSATION

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    SECTION 3 E BASED ON ORDINARY SHARES. SALES WERE PERFORMED AS PART OF AN ESTABLISHED 10B51 PLAN ADOPTED IN AUGUST 2025
    Date of Notice
    03/05/2026
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    08/10/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    CONFORMED SIGNATURE ON FILE

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $TEVA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TEVA

    DatePrice TargetRatingAnalyst
    12/9/2025$35.00Overweight
    Barclays
    12/5/2025$35.00Sector Outperform
    Scotiabank
    6/6/2025$24.00Buy
    Goldman
    5/28/2025$25.00Buy
    Truist
    5/12/2025$23.00Neutral → Overweight
    Analyst
    7/10/2024$20.00Hold → Buy
    Argus
    3/8/2024$14.00Underweight → Neutral
    JP Morgan
    2/12/2024$12.00 → $19.00Neutral → Overweight
    Piper Sandler
    More analyst ratings

    $TEVA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug

    Blackstone Life Sciences will provide $400 million to support development of duvakitug, a human monoclonal antibody targeting TL1ADuvakitug is currently in phase 3 clinical studies for ulcerative colitis (UC) and Crohn's disease (CD)Agreement supports Teva's Pivot to Growth strategy to accelerate its innovative pipeline and drive long-term growth PARSIPPANY, N.J. and CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and funds managed by Blackstone Life Sciences ("BXLS") today announced a $400 million strategic funding agreement spread across four years to support the continued clinical d

    3/3/26 5:00:00 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Teva to Present at the Upcoming Investor Conferences in March

    PARSIPPANY, N.J. and TEL AVIV, Israel, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will participate in the upcoming investor conferences in March as follows: UBS European Healthcare Conference Tuesday, March 3, 2026 (investor meetings only – no webcast)Leerink Partners Global Healthcare ConferenceMonday, March 9, 2026, at 10:00 am ET (webcast fireside chat)Barclays 28th Annual Global Healthcare ConferenceTuesday, March 10, 2026, at 8:00 am ET (webcast fireside chat) To access live webcasts of the presentations, please visit Teva's Investor Relations website at https://ir.tevaph

    2/24/26 4:30:00 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    U.S. Food and Drug Administration (FDA) Accepts Teva's New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

    Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation1If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations1Teva is committed to advancing this innovative treatment option and further building on its differentiated LAI franchise and scientific leadership in complex neurological conditions as it drives forward its Pivot to Growth strategy PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of

    2/20/26 2:43:11 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TEVA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Chief Legal Officer Mcavoy David R. bought $20,988 worth of Ordinary Shares (1,113 units at $18.86), increasing direct ownership by 9% to 13,027 units (SEC Form 4)

    4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)

    9/9/25 4:02:56 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TEVA
    SEC Filings

    View All

    SEC Form 144 filed by Teva Pharmaceutical Industries Limited

    144 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)

    3/5/26 5:49:15 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Teva Pharmaceutical Industries Limited

    10-K - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Filer)

    2/3/26 8:58:40 AM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Teva Pharmaceutical Industries Limited filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Filer)

    1/28/26 7:20:32 AM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TEVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Weiss Amir converted options into 5,179 units of Ordinary Shares, increasing direct ownership by 92% to 10,829 units (SEC Form 4)

    4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)

    3/5/26 4:11:31 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Europe Commercial Daniell Richard sold $4,173,942 worth of Ordinary Shares (128,985 units at $32.36) and converted options into 203,728 units of Ordinary Shares, increasing direct ownership by 154% to 123,127 units (SEC Form 4)

    4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)

    3/5/26 4:09:51 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    See "Remarks" Sabag Mark converted options into 166,378 units of Ordinary Shares, increasing direct ownership by 315% to 219,206 units (SEC Form 4)

    4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)

    3/5/26 4:08:17 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TEVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Teva Pharma with a new price target

    Barclays initiated coverage of Teva Pharma with a rating of Overweight and set a new price target of $35.00

    12/9/25 8:54:12 AM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Scotiabank initiated coverage on Teva Pharma with a new price target

    Scotiabank initiated coverage of Teva Pharma with a rating of Sector Outperform and set a new price target of $35.00

    12/5/25 8:41:58 AM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on Teva Pharma with a new price target

    Goldman initiated coverage of Teva Pharma with a rating of Buy and set a new price target of $24.00

    6/6/25 8:33:51 AM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TEVA
    Leadership Updates

    Live Leadership Updates

    View All

    Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma's Biggest Challenges

    First cohort features 7 real-world challenges across R&D, manufacturing and supply chain, commercial and medical affairs Teva's first-ever global innovation platform aims to accelerate patient impact and drive business transformation, as part of its Pivot to Growth StrategyRise will enable startups and tech players worldwide to validate their solutions in real-world settings, scaling impact across Teva's global ecosystem including in the U.S., Europe, Israel and beyond TEL AVIV, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today unveiled Teva Rise, a global open innovation platform designed to harness the power of a variety of disruptive tech

    11/19/25 8:00:00 AM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?

    USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 26, 2025 /PRNewswire/ -- USA News Group News Commentary – With analysts forecasting the global oncology drug market to surpass US$900 billion by 2034, investor interest in cancer-focused biotechs is rapidly intensifying. ResearchAndMarkets and Vision Research Reports both point to strong double-digit growth, citing surging demand for next-gen diagnostics and immunotherapies. Yet even as market potential grows, the U.S. public health sector is facing potential setbacks. Budget proposals suggest National Cancer Institute (NCI) funding could be slashed by up to 40%, while Bloomberg highlights concerns 

    6/26/25 11:44:00 AM ET
    $ADCT
    $CTOR
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Matthew Shields as Executive Vice President of Teva Global Operations (TGO), the Company's manufacturing and supply division, effective June 3, 2024. Mr. Shields succeeds Eric Drapé, who is leaving after 11 years with the Company, including more than four years as Executive Vice President, Global Operations. Mr. Shields will be a member of Teva's Executive Leadership Team and report directly to President and CEO Richard Francis. He will be based in Teva's U.S. headquarters in Parsippany, NJ. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2

    5/15/24 8:15:00 AM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TEVA
    Financials

    Live finance-specific insights

    View All

    Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential

    Teva delivers 3 consecutive years of growth - 2025 revenues of $17.3 billion, an increase of 4% year-over-year (YoY) in U.S. dollars, or 3% in local currency (LC) terms, compared to 2024. Excluding Japan BV, revenues increased 5% YoY in LC.Key Innovative brands continued to drive growth and provide value for patients, with 2025 revenues surpassing $3 billion, +35% YoY in LC: AUSTEDO® global revenues of $2.26 billion, growing 34% YoY in LC. AJOVY® global revenues of $673 million, up 30% YoY in LC.UZEDY® revenues of $191 million, up 63% YoY in LC; underscoring Teva's commitment to drive new advances in neuroscience: Fastest growing long-acting injectable (LAI)1FDA expanded indicati

    1/28/26 7:00:00 AM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

    Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million to support Teva's anti-IL-15 candidate TEV-‘408TEV-‘408 is currently in Phase 1b for treatment of vitiligo and in Phase 2a for celiac diseaseFunding agreement supports Teva's Pivot to Growth strategy to accelerate its innovative pipeline and bring treatments to patients faster PARSIPPANY, N.J., and NEW YORK, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Royalty Pharma plc (NASDAQ:RPRX), today announced a funding agreement of up to $500 million to accel

    1/11/26 5:00:00 PM ET
    $RPRX
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Teva Releases Q4 2025 Aide Memoire

    TEL AVIV, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q4 2025 Aide Memoire is available on the "Investors" page on its website. Q4 2025 Aide Memoire Teva has compiled this document with public information that was previously provided by Teva in order to assist investors ahead of fourth quarter 2025 results, which are expected to be released on Wednesday, January 28, 2026 at 7am ET, followed by a conference call at 8am ET. The document is based on Teva's prior results, management's previous commentary about Teva's business outlook and data from select independent sources. About Teva Teva Pharmaceutical Indu

    12/12/25 4:30:00 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TEVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Teva Pharmaceutical Industries Limited

    SC 13G - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)

    11/12/24 10:34:14 AM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Teva Pharmaceutical Industries Limited (Amendment)

    SC 13G/A - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)

    4/9/24 10:26:26 AM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Teva Pharmaceutical Industries Limited

    SC 13G - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)

    2/1/24 8:03:56 AM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care